A carregar...
Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials
OBJECTIVES: Fear of opioid withdrawal syndrome (OWS) often dissuades opioid discontinuation. Lofexidine is an FDA-approved, alpha(2)-adrenergic receptor agonist for treatment of OWS. Pivotal trial results from the per-protocol statistical analyses have been published. However, the FDA prescribing in...
Na minha lista:
| Publicado no: | J Drug Assess |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6968526/ https://ncbi.nlm.nih.gov/pubmed/32002194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1704416 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|